A Phase IIa Clinical Study to Evaluate the Efficacy and Safety of YN001 in Patients With Coronary Atherosclerosis in Australia
Latest Information Update: 27 Nov 2024
Price :
$35 *
At a glance
- Drugs Evolocumab (Primary) ; YN 001 (Primary)
- Indications Atherosclerosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Beijing Inno Medicine
- 27 Nov 2024 New trial record